HC Wainwright Reiterates “Buy” Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Monday, Benzinga reports. They presently have a $100.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 149.07% from the company’s previous close.

A number of other research firms have also recently commented on MLTX. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Monday, June 10th. The Goldman Sachs Group assumed coverage on shares of MoonLake Immunotherapeutics in a research report on Tuesday, April 2nd. They issued a “neutral” rating and a $62.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $92.00 target price on shares of MoonLake Immunotherapeutics in a research report on Wednesday, March 13th. Finally, Oppenheimer assumed coverage on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 25th. They issued an “outperform” rating and a $104.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.00.

MoonLake Immunotherapeutics Stock Down 3.9 %

NASDAQ MLTX opened at $40.15 on Monday. MoonLake Immunotherapeutics has a 12-month low of $35.11 and a 12-month high of $64.98. The company has a market capitalization of $2.57 billion, a PE ratio of -53.53 and a beta of 1.25. The firm’s 50 day moving average is $41.35 and its 200-day moving average is $49.09.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Sunday, May 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, sell-side analysts expect that MoonLake Immunotherapeutics will post -1.21 EPS for the current year.

Institutional Trading of MoonLake Immunotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System raised its holdings in shares of MoonLake Immunotherapeutics by 2.7% during the first quarter. California State Teachers Retirement System now owns 16,366 shares of the company’s stock valued at $822,000 after acquiring an additional 429 shares in the last quarter. Quarry LP bought a new position in MoonLake Immunotherapeutics in the fourth quarter worth $51,000. PNC Financial Services Group Inc. raised its holdings in MoonLake Immunotherapeutics by 50.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,147 shares of the company’s stock worth $371,000 after purchasing an additional 2,067 shares in the last quarter. Stratos Wealth Partners LTD. bought a new position in MoonLake Immunotherapeutics in the fourth quarter worth $202,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in MoonLake Immunotherapeutics in the fourth quarter worth $217,000. Institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.